ARGX-117 (anti-Complement C2) a humanized inhibitory monoclonal antibody against complement C2. ARGX-117 (anti-Complement C2) prevents the formation of the C3 proconvertase and inhibits classical and lectin pathway activation upstream of C3 activation through binding to the Sushi-2 domain of C2. ARGX-117 (anti-Complement C2) exhibits pH- and calcium-dependent target binding. ARGX-117 (anti-Complement C2) prevents complement-mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Protein Function
Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor 4b to generate the C3 or C5 convertase.